MULTIPLE SCLEROSIS FATIGUE AND RELATIONSHIP TO DEPRESSION AND PHYSICAL DISABILITY

Yıl 2001, Cilt: 14 Sayı: 3, 173 - 175, 03.12.2016

Dilek İnce Günal Meliha Güleryüz Nazire Avşar Sevinç Aktan

Öz

Objective: Psychiatric evaluation of 50 essential tremor (ET) patients was performed to determine the coexistent psychopathologies. The patients with positive psychopathologies were intended to treat by appropriate medication to demonstrate a positive effect of the treatment to tremor severity.
Methods: Symptom check list (SCL - 90R) and structural clinical interview-nonpatient (SCID-NP) were used as screening tests for psychopathologic symptoms. The patients with positive psychiatric findings according to DSM IV criteria were asked to use appropriate medication for 6 weeks in addition to their antitremor drugs. Alprazolam 0.75 mg daily was used for generalized anxiety disorder and social phobia, and sertraline 50 mg daily was given for affective disorder. Tremor severity was assessed by a standard scale before and after treatment.
Results: The results revealed the presence of anxiety disorder in 42 %, social phobia in 18 %, and affective disorder in 16 % of the patients. Administration of alprazolam to patients with anxiety disorders demonstrated a statistically significant improvement in tremor severity (p<0.05), however, in patients with social phobia and affective disorders no significant
improvement was observed after alprazolam or sertraline treatment, respectively.
Conclusion: Although the present study lacked a post-treatment psychiatric evaluation and had a limited study period of 6 weeks to identify the effect of present psychopathology on tremor severity, the observed frequent coexistence of psychopathologies and ET was quite remarkable. The results reinforced the positive effect of alprazolam on tremor control of ET patients with anxiety disorder. However, we could not demonstrate a significant improvement in tremor severity following treatment in ET patients having social phobia or dysthimic symptoms.
Key Words: Essential tremor, Psychopathology, Treatment, Coexistent

Kaynakça

• Holler WC, Busenbark KL. Essential tremor. In: Watts KL, Holler WC, eds. Movement Disorders. NY: McGraw Hill Companies, 1997:365-386.
• Deuschl G, Bain P, Brin M. Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 1998; 13 (suppl 3): 2-23.
• Derogatis LR. SCL 90R, administration, scoring and procedures manual-1 for the R(evised) version. Baltimore, MD: Johns Hopkins University School of Medicine, 1977.
• DSM IV: Diagnostic and Statistical Manual of
• Mental Disorders (Fourth Edition). Washington: American Psychiatric
• Association, 1994.
• Schroeder D, Nasrallah HA. High alcoholism rate in essential tremor patients. Am J Psychiatry 1982; 139: 1471-1473.
• Holler WC. Alcholism in essential tremor. Neurology 1983; 33: 1074-1076.
• Huber SJ, Paulson G W. Efficacy of alprazolam for essential tremor. Neurology 1988; 38: 241-243.
• Ince D, Aktan S. New therapeutic alternatives
• for essential tremor: Alprazolam and
• acetazolamide ( A placebo controlled doubleblind study). Mov Disord 1994; 9 (suppl I) : 23.
• Bain PG, Findley LJ, Thompson PD. A study of hereditary essential tremor. Brain 1994; 11 7: 805-824.
• Holler WC, Busenbark HL, Miner H. The relationship of essential tremor to other movement disorders: Report of 678 patients. Essential tremor study group. Ann Neurol 1994; 35: 717-723.
• 1. Scheidt CE, Schuller B, Rayki O, Hommerell G, Deusch G. Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm. Neurology 1996; 47: 43-45.